期刊
FRONTIERS IN IMMUNOLOGY
卷 11, 期 -, 页码 -出版社
FRONTIERS MEDIA SA
DOI: 10.3389/fimmu.2020.595342
关键词
coronavirus disease 2019; cytokine storm; cholinergic anti-inflammatory pathway; therapeutic strategy; vagus nerve stimulation
类别
资金
- National Natural Science Foundation of China [2018ZX09711002-003-015, 81773726, 82003981]
- National Key Research and Development Program of China [2020YFC0845400, 2017YFC1700200]
- Shanghai Sailing Program [19YF1459500]
- Science and Technology Innovation Action Plan Project [19401900100, 19431901400]
- National Science and Technology Major Project
This study suggests that activating the cholinergic anti-inflammatory pathway (CAP) may be a potential therapeutic strategy for COVID-19. Substances such as nicotine can activate the CAP and exert anti-inflammatory effects both in vitro and in vivo.
The outbreak of coronavirus disease 2019 (COVID-19) underlined the urgent need for alleviating cytokine storm. We propose here that activating the cholinergic anti-inflammatory pathway (CAP) is a potential therapeutic strategy. However, there is currently no approved drugs targeting the regulatory pathway. It is evident that nicotine, anisodamine and some herb medicine, activate the CAP and exert anti-inflammation action in vitro and in vivo. As the vagus nerve affects both inflammation and specific immune response, we propose that vagus nerve stimulation by invasive or non-invasive devices and acupuncture at ST36, PC6, or GV20, are also feasible approaches to activate the CAP and control COVID-19. It is worth to investigate the efficacy and safety of the strategy in patients with COVID-19.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据